Day: November 24, 2020

SUNNYVALE, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — JFrog, the liquid software company, today announced its participation in the following upcoming investor conferences.Wells Fargo TMT SummitPresentation: Wednesday, December 2, 2020, at 9:00 am PTMorgan Stanley Future of Application Development ConferencePresentation: Wednesday, December 9, 2020, at 9:45 am PTLive webcasts, as well as replays, will be available on the Company’s investor relations website at https://investors.jfrog.com/events-and-presentations/events.About JFrogJFrog is on a “Liquid Software” mission to enable the flow of software seamlessly and securely from the developer’s keystrokes to production. The end-to-end, hybrid JFrog Platform provides the tools and visibility required by modern software development organizations to fully embrace the power of DevOps....

MARIETTA, Ga., Nov. 24, 2020 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place December 1-3, 2020.A pre-recorded presentation will be available on the Events page of the Investors section of the Company’s website at www.mimedx.com beginning on November 25, 2020 at 5:00 PM Eastern Time and will be accessible for approximately 45 days.About MiMedxMiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes...

                             Paris, le 24 novembre 2020CommuniquéEn l’absence de financement bancaire comme d’apports par d’autres actionnaires, la société FIPP, actionnaire de la société FONCIERE PARIS NORD (FPN), assurait depuis plusieurs années le financement de la société PAMIER, unique filiale de FONCIERE PARIS NORD, en conditionnant ses prêts par l’octroi de garanties fortes, notamment un nantissement sur les titres de PAMIER.Le 27 octobre dernier, au regard de l’incapacité de la société PAMIER comme celle de son actionnaire FONCIERE PARIS NORD à rembourser ses dettes vis-à-vis de FIPP, à financer la lourde restructuration du site immobilier situé à Blanc-Mesnil (Centre d’Affaires Paris Nord) ou même à financer les dépenses nécessaires pour permettre la cession du site en l’état (travaux de désamiantage notamment), la société FIPP...

NORWALK, Conn., Nov. 24, 2020 (GLOBE NEWSWIRE) — Reed’s Inc. (Nasdaq: REED), owner of the nation’s leading portfolio of handcrafted, all-natural beverages, today announced it has closed its previously announced underwritten public offering of 18,750,000 shares and the full exercise of the underwriters’ option to purchase an additional 2,812,500 shares. In total, the Company issued 21,562,500 of its common stock at a price of $0.56 per share for gross proceeds of approximately $12.1 million. Included within the total offering amount, members of Reed’s Board of Directors and senior management invested in the aggregate of approximately $625,000.“The success of this offering and insider participation is a testament to our collective confidence in our long-term growth potential. We are driving accelerated growth, driven by strong execution...

CRANBURY, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will present on Wednesday, December 2, 2020 at the Evercore ISI 3rd Annual HealthCONx Conference. The presentation will also be available on PMV’s web site. Details on the presentation can be found below.Evercore ISI 3rd Annual HealthCONx ConferenceAbout PMV PharmaPMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 is mutated in approximately half of all cancer. The field of p53 biology was established by our co-founder Dr....

PLANO, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) completed its internal review of the Baseline-Controlled Study results of omaveloxolone for the treatment of patients with Friedreich’s ataxia (“FA”) and concluded that the results do not strengthen the results of Part 2 of the MOXIe study. The FDA proposed some additional exploratory analyses using patients randomized to placebo during the MOXIe Part 2 study, but stated that the potential for these analyses to strengthen the study results was questionable due to the small number of patients available for analysis. The FDA stated that they remain interested in reviewing the results of the additional...

GUANGZHOU, China, Nov. 24, 2020 (GLOBE NEWSWIRE) — The board of directors of Fanhua Inc. (“Fanhua” or “the Company”) (Nasdaq: FANH), a leading independent financial services provider in China, today announced that its Board of Directors (the “Board”) has declared a quarterly dividend of US$0.0125 per ordinary share, or US$0.25 per ADS for the third quarter of 2020. The dividend is payable on or around Dec 23, 2020 to shareholders of record on Dec 9, 2020.About Fanhua Inc.Fanhua Inc. is a leading independent financial services provider. Through our online platforms and offline sales and service network, we offer a wide variety of financial products and services to individuals, including life and property and casualty insurance products. We also provide insurance claims adjusting services, such as damage assessments, surveys, authentications...

EDMONTON, Alberta, Nov. 24, 2020 (GLOBE NEWSWIRE) —  TSX, NYSE: STNStantec Inc. (“Stantec”) today announced the appointment of Martin à Porta to the Board of Directors of Stantec effective January 1, 2021.Martin à Porta is an experienced executive and consultant with 25 years of experience working in and supporting professional services and industrial companies, including Siemens, where he worked for more than a decade in several progressively senior roles around the world. Most recently, Mr. à Porta served as the President and CEO of Pöyry Plc, an international consulting and engineering company, providing services in power generation, transmission, and distribution; forestry; biorefining and chemicals; mining and metals; infrastructure; water, and environmental services. Mr. à Porta currently provides transformation, growth,...

TORONTO, Nov. 24, 2020 (GLOBE NEWSWIRE) — The Flowr Corporation (TSX.V: FLWR; OTC: FLWPF) (“Flowr” or the “Company”) herein announces its financial and operational results for the third quarter ended September 30, 2020.  Key financial and operating highlights in the third quarter of 2020:The Company generated gross revenue of approximately $3.5 million in the third quarter, a 64% increase as compared to the same period in 2019 and a 15% increase sequentially from the second quarter in 2020.Net revenue in the third quarter 2020 was $2.8 million, a 110% increase as compared to the same period in 2019 and up 22% sequentially from the second quarter in 2020.During the quarter, the Company sold 552 kilograms of dried flower, an increase of 144% as compared to the same period in 2019 and up 31% sequentially from the second quarter 2020....

Combines Codexis’ R&D and commercialization platform with Casdin Capital’s investment expertise to invest in and support innovative early stage life science and synthetic biology technology companiesInaugural investment in Arzeda Corp., a next generation protein design companyAccelerator is a key component of Casdin’s plans to invest upwards of $50 million into sectorREDWOOD CITY, Calif. and NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading Synthetic Biology company developing and supplying differentiated enzyme products for high value markets, in collaboration with leading life science investor Casdin Capital, announce the launch of SynBio Innovation Accelerator. The goal of the accelerator is to fund and nurture early stage companies with disruptive technology platforms or unique product development...